Liquidators of biotech startup in talks over stake in drug firm
Subscribe to BusinessDesk
Stay informed on business, government and financial developments across New Zealand.
- Stay informed on business, government and financial developments across New Zealand.
- Deeply researched, twice-edited and fact-checked news
- Annual subscribers also receive a complimentary subscription to The Wall Street Journal
- Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers
You can cancel anytime with two clicks, an email or a phone call.
Find out
more.
We are serious about journalism.
All subscriptions auto renew but are easy to cancel.
Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}
Or use the information you’ve already given Google to create your subscription.
Not convinced yet?
Subscribe to our free 7am Headlines newsletter.
A quick summary of everything BusinessDesk has published in the previous 24 hours. No BusinessDesk
subscription needed.
'Rolling maul' of Govt economy announcements
Nicola Willis plans to make a lot of policy announcements around growth.
Lyttelton Port looks to 19th century for modern operations
The port is the first company in NZ to release a nature-based disclosure report.
The inflation beast is back in its cave
The RBNZ will likely cut by another 50bps in February, but then the pace will slow.
Shining bright: Why gold matters today
The “great wealth store” remains a smart portfolio choice in 2025.
Why Kiwis are embracing Bitcoin ETFs
The once hard-to-access investment option is becoming mainstream.
